We sought to determine the optimal dose of the selective endothelin A (ET A ) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for observation only, an open-label (OL) bosentan arm was included. BACKGROUND Endothelin is a mediator of PAH. In a preliminary PAH study, the selective ET A receptor antagonist sitaxsentan improved six-min walk (6MW) distance, World Health Organization (WHO) functional class (FC), and hemodynamics.
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by vasoconstriction and structural changes in small pulmonary arteries, with increased pulmonary artery pressure and pulmonary vascular resistance ultimately leading to right heart failure and death (1) . Endothelin-1 (ET), a 21-amino acid peptide with vasoconstrictor, mitogenic, and profibrotic effects (2), appears to play a key role in the pathobiology of PAH (3, 4) . Two distinct ET receptor isoforms have been identified, ET A and ET B (5) . Endothelin A receptors are expressed on smooth muscle cells and cardiac myocytes; ET B receptors are localized on vascular endothelial cells and smooth muscle cells (6) . Activation of ET A and ET B receptors on smooth muscle cells results in vasoconstriction, and cell proliferation and hypertrophy. Activation of ET B receptors on endothelial cells leads to release of vasodilators, i.e., nitric oxide and prostacyclin, which also appear to have antiproliferative properties (7, 8) ; in addition, endothelial ET B receptors are involved in the clearance of ET-1, primarily in the vascular beds of the lungs, kidneys, and liver (9) .
To date, bosentan, an ET A /ET B receptor antagonist, is the only approved ET receptor antagonist for the treatment of PAH (10, 11) . Sitaxsentan sodium is a selective ET A receptor antagonist, i.e., ET A :ET B ratio Ͼ6,500:1, with a high oral bioavailability (Ͼ90%) and a long duration of action (half-life ϳ10 h in PAH patients) (12) . Although the Sitaxsentan To Relieve ImpaireD Exercise-1 (STRIDE-1) study demonstrated improved exercise capacity (as assessed by the six-min walk [6MW] test), World Health Organization (WHO) functional class (FC), cardiac index, and pulmonary vascular resistance at both sitaxsentan doses studied, i.e., 100 and 300 mg orally once daily, the safety profile was unacceptable with the 300-mg dose (13) . The objective of this study was to confirm the efficacy of sitaxsentan and to determine the optimal dose on the basis of overall risk-to-benefit considerations, i.e., safety and tolerability with therapeutic efficacy. On the basis of the perception that 100 mg was the optimal dose in the STRIDE-1 study, the STRIDE-2 study was powered to show statistical difference of the primary efficacy end point between the sitaxsentan 100 mg and placebo groups. For observation only, an open-label (OL) (6MW tests, Borg dyspnea scores, and WHO FC assessments third-party blind) bosentan arm was included. Patients in WHO FC II, III, or IV, 12 to 78 years of age, with symptomatic PAH despite treatment with anticoagulants, vasodilators, diuretics, cardiac glycosides, and/or supplemental oxygen (as clinically indicated) were eligible for study participation if they met the following criteria: 1) PAH that was idiopathic, associated with connective tissue disease, or associated with repaired atrial septal defect, ventricular septal defect, or patent ductus arteriosus at least one year before study enrollment; in addition, patients with PAH associated with an unrepaired secundum atrial septal defect (with a resting systemic arterial oxygen saturation of Ն88% in room air) were eligible; 2) mean pulmonary artery pressure Ն25 mm Hg at rest, pulmonary capillary wedge pressure or left ventricular end diastolic pressure Յ15 mm Hg, and pulmonary vascular resistance Ն3 Wood units (obtained by right heart catheterization within six months of study enrollment [to confirm the diagnosis of PAH]); and 3) baseline 6MW distance Ն150 m and Յ450 m. For patients Ͻ18 years of age, body weight was Ն50 kg. Patients were excluded if they had significant parenchymal lung disease, portal hypertension, chronic liver disease, human immunodeficiency virus infection, hepatic dysfunction (hepatic transaminase level Ͼ1.5ϫ the upper limit of normal [ULN]), renal insufficiency, history of left-sided heart disease, history of obstructive sleep apnea (treated or untreated), previously failed bosentan due to safety or inadequate clinical response (in the judgment of the investigator), were on a prostaglandin, phosphodiesterase inhibitor, or an ET receptor antagonist, or had received any new type of PAH treatment within 30 days before study entry.
METHODS

Study population.
The study was conducted according to ethical principles stated in the Declaration of Helsinki (1996) and applicable guidelines on good clinical practice. The protocol was approved by local institutional review committees; written informed consent was obtained from all patients. Study design and randomization. The study was an international, multicenter, randomized, double-blind, placebo-controlled trial that treated 245 patients between July 2003 and January 2005, at 55 sites. Patients were randomized to receive placebo, sitaxsentan 50 mg, or sitaxsentan 100 mg orally once daily, or OL bosentan for 18 weeks. The OL bosentan arm was included for observation only. The bosentan arm was OL at the standard dose, i.e., 62.5 mg orally twice daily for four weeks, then increasing to the maintenance dose of 125 mg orally twice daily. Because bosentan is only available commercially on a named-patient basis, blinded drug supplies were not available. Patients randomized to bosentan received OL drug (site personnel obtained medication through commercial channels utilizing the bosentan Access Program); however, the efficacy rater was blinded for the 6MW tests, WHO FC assessments, and Borg dyspnea scores, i.e., third-party blind. Randomization was performed centrally according to a computer-generated random number table. Randomization was 1:1:1:1. At the end of the 18-week study, all patients who completed the 18-week trial were eligible to enter an extension study. Patients who had been randomized, double-blind, to sitaxsentan 50 mg or 100 mg in the STRIDE-2 study received sitaxsentan 100 mg in the extension; patients who had been randomized to OL bosentan in the STRIDE-2 study continued OL bosentan in the extension. Patients who had been randomized, double-blind, to placebo in the STRIDE-2 study were randomized to either sitaxsentan 100 mg or OL bosentan in the extension. The STRIDE-2 randomization for patients randomized to sitaxsentan 50 mg or 100 mg in the STRIDE-2 study remained double-blind until the STRIDE-2 study database was locked; the STRIDE-2 randomization for patients randomized to placebo in the STRIDE-2 study and randomized to sitaxsentan 100 mg in the extension study remained double-blind until the STRIDE-2 study database was locked. Patients receiving OL bosentan remained third-party blind throughout the STRIDE-2 study and in the extension until the STRIDE-2 study database was locked. Outcome measures. Patients were evaluated at baseline and at weeks 6, 12, and 18. The primary end point was change from baseline in 6MW distance at week 18. Secondary end points included change in WHO FC, time to clinical worsening, and change in Borg dyspnea score. Safety was assessed by adverse events and laboratory evaluations. Patients receiving sitaxsentan or placebo were discontinued if they had an elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) Ͼ5ϫ ULN, or if they had an elevation in total bilirubin Ͼ2ϫ ULN with an ALT or AST Ͼ3ϫ ULN. For OL bosentan patients, liver function abnormalities were handled according to the bosentan package insert, i.e., a patient was to be discontinued if ALT or AST exceeded 8ϫ ULN, although the patient could undergo bosentan dosage reductions or temporary cessation for lesser elevations in ALT or AST at the discretion of the investigator. Investigators had the option to discontinue patients from the study if patients had a combined deterioration in WHO FC and Ն15% decrease in 6MW distance from baseline. Patients completing the 18-week study (all groups) or prematurely discontinuing (50-mg or placebo groups) were eligible to enter the STRIDE-2X extension study. Statistical analysis. Data are reported as mean Ϯ SD unless otherwise stated. The STRIDE-2 study was powered to identify statistical differences in efficacy between the 100-mg sitaxsentan and placebo groups. Comparisons between sitaxsentan and OL bosentan were observational only because of the inability to double-blind the bosentan arm.
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As defined in the protocol, for reporting statistical significance of efficacy, adjustments were made for multiple comparisons of multiple end points in treatment groups. Statistical significance was reported only if the conditions for the multiple comparison strategy were met; a p value Ͻ0.05 was considered statistically significant. The primary end point was the change in 6MW distance from baseline to week 18. On the basis of the STRIDE-1 study data, an approximate 35-m difference between the 100 mg sitaxsentan and the placebo treatment groups, with a standard deviation of 58 m in each treatment group in the change from baseline in 6MW distance at week 18, was used to calculate the sample size of approximately 60 subjects per treatment group to detect statistically significant differences with 90% power at the significance level of 0.05 using a two-sided Student t test. The null hypothesis of no difference between treatment groups was tested using the non-parametric analysis of covariance (ANCOVA), adjusted for baseline values. All missing values were imputed using the last observation carried forward method. If the patient was unable to perform the 6MW test because of clinical worsening or death, the 6MW distance was assigned a value of 0 m with a Borg dyspnea score of 10 for the visit.
Secondary end points were change from baseline to week 18 in WHO FC, time to clinical worsening, and Borg dyspnea score. Change from baseline in WHO FC was summarized with frequency counts and percentages, and treatment difference was analyzed using the CochranMantel-Haenszel test, controlling for baseline WHO FC. The Kaplan-Meier method was used to estimate time to clinical worsening. Time to clinical worsening was defined as the number of days between the first dose date and the first date when clinical worsening occurred. Patients who discontinued or completed the study without having a clinical worsening event were censored at their last visit. Clinical worsening was defined as any of the following: hospitalization for PAH, death, transplantation, atrial septostomy, initiation of new chronic PAH treatment, or combined WHO FC deterioration and Ն15% decrease in 6MW distance from baseline. Treatment differences were evaluated using log-rank tests. The change in Borg dyspnea score from baseline to week 18 was analyzed using the non-parametric ANCOVA, adjusted for baseline values.
All efficacy analyses were conducted on the intent-totreat (ITT) population, which was defined as all randomized patients who took any dose of study drug and performed at least one valid post-baseline 6MW test. Interim monitoring. An independent external Data Safety Monitoring Board (DSMB) conducted an interim safety evaluation on the basis of adverse events and laboratory data after 60 patients completed week 12 assessments. In addition, the DSMB reviewed serious adverse events and elevated hepatic transaminases by blinded, masked treatment on an ongoing basis. Only the DSMB was authorized to request unblinding of safety data by treatment groups.
RESULTS
Patients. Two hundred forty-seven patients were randomized, 245 patients treated: 62 patients received placebo, 62 patients received sitaxsentan 50 mg, 61 patients received sitaxsentan 100 mg, and 60 patients received OL bosentan. Five patients did not have a valid post-baseline 6MW test; i.e., there were 240 patients in the ITT population for efficacy end points. Thirty-one patients prematurely discontinued the study (Fig. 1) . The primary reason given for discontinuation in the placebo group (n ϭ 11) was elevation of AST or ALT Ͼ3ϫ ULN and total bilirubin Ͼ2ϫ ULN in one patient, WHO FC deterioration and Ն15% decrease in 6MW distance in two patients, initiation of new chronic PAH treatment in five patients, adverse event in two patients, and sponsor decision in one patient. In the sitaxsentan 50 mg group, eight patients discontinued: WHO FC deterioration and Ն15% decrease in 6MW distance in one patient, initiation of new chronic PAH treatment in three patients, adverse event in one patient, patient decision in two patients, and investigator decision in one patient. In the sitaxsentan 100 mg group, four patients discontinued: elevation of AST or ALT Ͼ5ϫ ULN in one patient, initiation of new chronic PAH treatment in two patients, and patient decision in one patient. In the OL bosentan group, eight patients discontinued: elevation in ALT or AST Ͼ8ϫ ULN in two patients, WHO FC deterioration and Ն15% decrease in 6MW distance in one patient, and initiation of new chronic PAH treatment in five patients. The patients who prematurely discontinued the study were not significantly different than the overall study
Patient characteristics for study entry are shown in Table 1 . Overall, PAH was idiopathic PAH in 59% of patients, associated with connective tissue disease in 30% of patients, and associated with congenital heart disease (as defined in the inclusion criteria) in 11% of patients. Baseline characteristics were similar for the four treatment groups, with the exception of baseline 6MW distance, age, and height. The distance of 6MW at baseline, therefore, was used as a covariate for efficacy analyses. Exercise capacity. At week 18 (Fig. 2) , the change from baseline in 6MW distance was 17.8 m in the sitaxsentan 50 mg group, 24.9 m in the sitaxsentan 100 mg group, and 23.0 m in the OL bosentan group. In contrast, a decrease of 6.5 m from baseline occurred in the placebo group at week 18, i.e., the placebo-subtracted treatment effects at week 18 in the sitaxsentan groups were 24.2 m (p ϭ 0.07) for the 50-mg group and 31.4 m (p ϭ 0.03; 95% confidence interval 5.37, 57.44) for the 100-mg group. For the OL third-party blind bosentan-treated patients, the placebosubtracted treatment effect at week 18 was 29.5 m (p ϭ 0.05). WHO FC. At week 18 (Fig. 3) , the change from baseline in WHO FC was significantly better for the sitaxsentan 100-mg group compared with those receiving placebo (p ϭ 0.04), i.e., 98% of the sitaxsentan 100-mg patients improved WHO FC (13%) or remained unchanged (85%), whereas 87% of the placebo patients improved WHO FC (10%) or remained unchanged (77%). No significant improvements were seen after 18 weeks in WHO FC versus placebo in either the sitaxsentan 50-mg group or the OL bosentan group. Worsening in WHO FC at week 18 (vs. baseline) occurred in 13% of placebo patients, 13% of sitaxsentan 50-mg patients, 2% of sitaxsentan 100-mg patients, and 9% of OL bosentan patients.
Time to clinical worsening. Twenty-nine patients (10 placebo, 6 sitaxsentan 50 mg, 4 sitaxsentan 100 mg, and 9 OL bosentan patients) experienced at least one clinical worsening event; the most frequently reported reasons for clinical worsening were initiation of new chronic PAH treatment (18 patients); combined deterioration in WHO FC and Ն15% decrease in 6MW distance (11 patients); and hospitalization for worsening PAH (10 patients) ( Table 2) . During the 18-week study, sitaxsentan 100 mg trended toward an increase in the time to clinical worsening versus placebo (p ϭ 0.08); there were no differences for either the sitaxsentan 50-mg group (p ϭ 0.27) or the OL bosentan group (p ϭ 0.80) compared with patients receiving placebo. Borg dyspnea score. Change from baseline to week 18 in Borg dyspnea score in the sitaxsentan 100-mg group showed a nonsignificant improvement (reduction in score), while the placebo group worsened (Ϫ0.01 vs. 0.19; p ϭ 0.6603). Changes from baseline to week 18 in Borg dyspnea score in the sitaxsentan 50-mg and OL bosentan groups also were not significantly different from patients receiving placebo. Safety. The number of patients reporting adverse events in each treatment group was similar; i.e., 90% of placebo patients, 86% of sitaxsentan 50-mg patients, 93% of sitaxsentan 100-mg patients, and 89% of OL bosentan patients experienced at least one adverse event. Treatment-related adverse events were reported in 29% of placebo patients, 36% of sitaxsentan 50-mg patients, 46% of sitaxsentan 100-mg patients, and 56% of OL bosentan patients. Serious adverse events occurred most often in placebo patients. Treatment-related side effects are listed in Table 3 ; edema, nasal congestion, fatigue, and insomnia were more frequently reported by sitaxsentan patients than by placebo patients, with a frequency that appeared to be dose-related (Table 3) . Eighteen patients discontinued the STRIDE-2 study because of an adverse event: six (10%) placebo patients, four (7%) sitaxsentan 50-mg patients, two (3%) sitaxsentan 100-mg patients, and six (10%) OL bosentan patients. Serious adverse events were more than twice as frequent in the placebo group (31%) compared with any of the other three groups, and were most often related to PAH worsening. Two patients in the placebo group died (due to multiple-organ failure), 5 and 15 days after premature discontinuation from the study. Serious adverse events of elevated hepatic transaminases considered related to a study drug occurred in one sitaxsentan 100-mg patient and in one OL bosentan patient. Bleeding adverse events, most commonly epistaxis, were reported in three placebo patients, eight sitaxsentan 50-mg patients, six sitaxsentan 100-mg 
All values shown are based on safety population. *Previous and concomitant treatment is defined as treatment taken at any time Յ3 days before. †Obtained by right heart catheterization within six months of study entry to confirm the diagnosis of PAH. All other characteristics are at baseline. Day 0 through study termination. Values are n (%) or mean Ϯ SD. BID ϭ twice a day; PAH ϭ pulmonary arterial hypertension; QD ϭ once daily; WHO ϭ World Health Organization.
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patients, and four OL bosentan patients. None of the bleeding events were considered serious or required hospitalization, transfusion, or treatment. Liver abnormalities have been recognized as a class effect associated with endothelin receptor antagonists (10, 11, 13, 14) . The incidence of liver enzyme abnormalities (hepatic transaminase values Ͼ3ϫ ULN) was 6% for the placebo group, 5% for those receiving sitaxsentan 50 mg, 3% for the sitaxsentan 100-mg patients, and 11% for the OL bosentan group. Elevations in liver enzymes were associated with drug discontinuation in one placebo patient, one 50-mg patient (Ͼ3ϫ ULN, with the reason for discontinuation reported as investigator decision), one 100-mg patient, and two OL bosentan patients. Liver enzyme abnormalities reversed in all sitaxsentan and bosentan cases.
Because of the effect of sitaxsentan on inhibition of the CYP2C9 P450 enzyme, the principal hepatic enzyme involved in warfarin metabolism, an 80% reduction in the warfarin dose for patients not randomized to OL bosentan was used at baseline, with adjustment as needed to maintain a therapeutic international normalized ratio (INR). The proportion of patients with an INR Ͼ3.5 was comparable for the sitaxsentan and placebo groups (33% to 42%) and lower for the OL bosentan group (20%) (p ϭ 0.1744). Dosage adjustments occurred with similar frequencies for the four groups (63 to 70 adjustments per group). Daily warfarin dosages at week 18 were: 3.7 Ϯ 2.7 mg/day for placebo patients, 2.8 Ϯ1.2 mg/day for 50-mg sitaxsentan patients, 2.1 Ϯ 1.0 mg/day for 100-mg sitaxsentan patients, and 5.1 Ϯ 2.9 mg/day for OL bosentan patients. Warfarin doses were similar to baseline for placebo patients, lower than baseline in the sitaxsentan patients, and higher than baseline in the bosentan patients.
Decreases in hemoglobin in sitaxsentan-and OL bosentan-treated patients were observed as early as week two and remained stable throughout the 18-week study (mean change from baseline to week 18: placebo, ϩ0.2 g/dl; 50 mg sitaxsentan, Ϫ0.2 g/dl; 100 mg sitaxsentan, Ϫ0.5 g/dl; and OL bosentan, Ϫ0.5 g/dl). A small and similar number of patients, i.e., one to three patients, for each four treatment groups using the Fisher exact test. ‡Two patients in the placebo group died (of multi-organ failure) 5 and 15 days after premature discontinuation from the study, and were not counted as events in the clinical worsening analysis. §Sitaxsentan n ϭ 1; bosentan n ϭ 2; oxygen n ϭ 1. ʈSitaxsentan n ϭ 2; sildenafil n ϭ 1; digoxin n ϭ 1. ¶Digoxin n ϭ 1; oxygen n ϭ 2. #SC treprostinil n ϭ 1; sitaxsentan n ϭ 1. FC ϭ functional class; OL ϭ open-label; 6MW ϭ six-min walk; other abbreviations as in Table 1 .
group shifted from the normal laboratory hemoglobin range to below the normal range by week 18. The DSMB did not request that data be unblinded during the study.
DISCUSSION
In a preliminary, randomized, controlled PAH trial (STRIDE-1), although both 100-and 300-mg doses of sitaxsentan improved exercise capacity (as assessed by the 6MW test), WHO FC, cardiac index, and pulmonary vascular resistance compared with placebo, the incidence of elevated hepatic transaminases (Ͼ3ϫ ULN), serious adverse events, and discontinuation were higher with the 300-mg dose, consistent with a dose response for safety and tolerability. On this basis, 100 mg was chosen as the highest dose to be studied in future trials.
On the basis of overall safety, tolerability, and efficacy, the STRIDE-2 study demonstrated that 100 mg is the optimal dose of sitaxsentan for treating symptomatic PAH. Treatment with sitaxsentan 100 mg significantly improved exercise capacity and WHO FC compared with placebo; 50 mg was subtherapeutic, and based on the results from the STRIDE-1 study, 300 mg was unacceptable for safety. Among the treatment-related side effects, edema, nasal congestion, fatigue, and insomnia were more frequently reported by the sitaxsentan-treated patients than by the placebo patients.
Patients with PAH are frequently anticoagulated; sitaxsentan inhibits warfarin metabolism via inhibition of CYP2C9, and bosentan induces CYP2C9 (15) . Dosage adjustments in warfarin were equally frequent in all four groups, with mean daily warfarin doses lower for sitaxsentan-treated patients (in a dose-dependent manner) compared with patients receiving placebo, and higher for OL bosentan-treated patients compared with the placebo group. Although increases in INR Ͼ3.5 occurred in a significant number of patients receiving placebo or sitaxsentan, bosentan patients were relatively protected from this effect, consistent with enzyme induction of warfarin metabolism with bosentan. However, in all groups, concomitant therapy with warfarin was well tolerated, and bleeding events were rare, non-serious, and did not require treatment.
Liver function abnormalities have been previously reported with endothelin receptor antagonists and can lead to treatment discontinuation. In the STRIDE-1 study and its extension (median exposure 26 weeks), 5% of patients treated with sitaxsentan 100 mg had Ͼ3ϫ ULN hepatic transaminases; all transaminase increases were reversible. Although the STRIDE-2 study was not powered to assess comparison between sitaxsentan 100 mg and OL bosentan, during this 18-week study, the incidence of elevated hepatic transaminases was 3% for sitaxsentan 100 mg and 11% for OL bosentan (i.e., the same as the rate reported in the bosentan package insert).
Pulmonary arterial hypertension is a rare and serious disease. Despite the scientific interest in comparing an ET A selective receptor antagonist with an ET A /ET B receptor antagonist, it was not possible to conduct a trial of sufficient power (in a reasonable period of time) to directly compare the efficacy of sitaxsentan with bosentan. Only a trial of considerable size, with both treatments administered double-blind, could resolve this question with certainty. Because of a unique distribution program, it was not possible to double-blind the bosentan arm in this study.
CONCLUSIONS
Treatment with the selective ET A receptor antagonist sitaxsentan (at a dose of 100 mg orally once daily) improves exercise capacity and WHO FC in symptomatic PAH patients, with a low incidence of hepatic toxicity. 
